GSK360A
Modify Date: 2024-01-02 18:37:28
GSK360A structure
|
Common Name | GSK360A | ||
|---|---|---|---|---|
| CAS Number | 931399-19-8 | Molecular Weight | 348.33 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C17H17FN2O5 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of GSK360AGSK360A is a potent and orally active HIF-PHD inhibitor with IC50 values of 10, 100, and 126 nM for PHD1, PHD2, and PHD3, respectively. GSK360A activates the HIF-1 alpha pathway and protect the failing heart after myocardial infarction (MI) [1]. |
| Name | 2-[[1-(2-cyclopropylethyl)-6-fluoro-4-hydroxy-2-oxoquinoline-3-carbonyl]amino]acetic acid |
|---|---|
| Synonym | More Synonyms |
| Description | GSK360A is a potent and orally active HIF-PHD inhibitor with IC50 values of 10, 100, and 126 nM for PHD1, PHD2, and PHD3, respectively. GSK360A activates the HIF-1 alpha pathway and protect the failing heart after myocardial infarction (MI) [1]. |
|---|---|
| Related Catalog | |
| In Vivo | GSK360A (30 mg/kg i.g.) 在已建立的心室功能障碍模型中改善长期心室功能、重塑和血管分布[1]。 Animal Model: male Lewis rats with ventricular dysfunction model[1] Dosage: 30 mg/kg Administration: oral gavage Result: Increased circulating levels of erythropoietin and hemoglobin and hemoxygenase-1 expression in the heart and skeletal muscle of male rats. |
| References |
| Molecular Formula | C17H17FN2O5 |
|---|---|
| Molecular Weight | 348.33 |
| Exact Mass | 348.11200 |
| PSA | 112.12000 |
| LogP | 2.03550 |
| gsk360a |